Chronic Kidney Disease

Oral Semaglutide Cuts MACE Risk by 14% in High-Risk Adults: Daily Dose

April 25, 2025

Your daily dose of the clinical news you may have missed.

Tirzepatide Improves Heart Failure Symptoms and Renal Function in People with Obesity, CKD

April 11, 2025

ACC 2025. Tirzepatide improved HF symptoms and renal function in patients with obesity-related HFpEF, regardless of CKD status, according to new findings from the SUMMIT trial.

Ozempic Approval Expanded to Include Patients with T2D and CKD: Daily Dose

February 13, 2025

Your daily dose of the clinical news you may have missed.

Lexicon Receives Complete Response Letter for Sotagliflozin in Type 1 Diabetes and Chronic Kidney Disease

January 03, 2025

In November 2024, an FDA advisory committee said the benefits of sotagliflozin do not outweigh the risks in adults with type 1 diabetes and chronic kidney disease.

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease

November 07, 2024

The data, published in JASN, were presented last week to an FDA advisory committee considering recommending sotagliflozin as an adjunct to insulin in adults with T1D and CKD.

Oral Semaglutide Shows 14% Reduction in MACE in Adults with T2D, ASCVD, and/or CKD: Topline Results from Phase 3 SOUL Trial

October 21, 2024

Novo Nordisk plans to file for regulatory approval this year of an expanded label for oral semaglutide, with an indication for reduction of MACE in high-risk adults with T2D.